Skip to content
Home/Companies/Biotech/AAVantgarde
AAVantgarde

AAVantgarde

Biotech·Italy·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns AAVantgarde?

AAVantgarde is currently owned by XGen Venture SGR through XGEN Venture Life Sciences Fund (2022 vintage), since 2025.

Hand-verified · updated 2026-07-23

XGen Venture SGR
Investor
XGen Venture SGR
XGEN Venture Life Sciences Fund · 2022 · Life Sciences VC

Key facts

HQItaly
SectorBiotech
StatusActive
Websitewww.aavantgarde.com

More from XGEN Venture Life Sciences Fund

Other portfolio companies in the same fund.

EpilepsyGTx
Active
BiotechUK· 2025
Gesynta Pharma
Gesynta Pharma
Active
BiotechSweden· 2025
Nanophoria
Active
BiotechItaly· 2025
Genespire
Genespire
Active
BiotechItaly· 2024
iOnctura
iOnctura
Active
BiotechSwitzerland· 2024
Page Therapeutics
Page Therapeutics
Active
BiotechSwitzerland· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track AAVantgarde

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy AAVantgarde?

6 strategic and 114financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on AAVantgarde.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue